|Day's Range||199.12 - 200.15|
|52 Week Range||164.80 - 200.83|
|PE Ratio (TTM)||N/A|
|Expense Ratio (net)||0.25%|
For fiscal 2018 (ended March 31, 2018), Abiomed (ABMD) has projected that its operating margins will be in the range of 22%–24%.
Two midcap growth funds are among those in buy range after breaking out Wednesday to new 52-week highs.
In 1Q17, Align Technology (ALGN) also witnessed a robust rise of around 45.2% in volumes of Invisalign sold in Asia-Pacific markets on a YoY basis.